NASDAQ: VIR
Vir Biotechnology Inc Stock

$31.36-1.52 (-4.62%)
Updated Jan 25, 2022
VIR Price
$31.36
Fair Value Price
$36.70
Market Cap
$4.10B
52 Week Low
$29.48
52 Week High
$83.50
P/E
-37.33x
P/B
4.68x
P/S
20x
PEG
N/A
Dividend Yield
N/A
Revenue
$284.39M
Earnings
-$102.32M
Gross Margin
96.8%
Operating Margin
-35.78%
Profit Margin
-36%
Debt to Equity
0.38
Operating Cash Flow
-$137M
Beta
0.01
Next Earnings
Feb 23, 2022
Ex-Dividend
N/A
Next Dividend
N/A

VIR Overview

Zen Score

High
Medium
Low
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VIR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VIR ($31.36) is undervalued by 14.55% relative to our estimate of its Fair Value price of $36.70 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
VIR is poor value based on its book value relative to its share price (4.68x), compared to the US Biotechnology industry average (4.53x)
Valuation
VIR's cash and short-term investments... subscribe to Premium to read more.
Financials
There are 15 more VIR due diligence checks available for Premium users.

VIR News

Valuation

VIR fair value

Fair Value of VIR stock based on Discounted Cash Flow (DCF)
Price
$31.36
Fair Value
$36.70
Undervalued by
14.55%
VIR ($31.36) is undervalued by... subscribe to Premium to read more.
Valuation

VIR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-37.33x
Industry
21x
Market
33.66x

VIR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.68x
Industry
4.53x
VIR is poor value based... subscribe to Premium to read more.
Valuation

VIR's financial health

Profit margin

Revenue
$103.6M
Net Income
$110.4M
Profit Margin
106.6%
VIR's cash and short-term investments... subscribe to Premium to read more.
Financials
VIR's profit margin has increased... subscribe to Premium to read more.
Financials

Assets to liabilities

Assets
$1.2B
Liabilities
$333.9M
Debt to equity
0.38
VIR's short-term assets ($1.07B) exceed... subscribe to Premium to read more.
Financials
VIR's short-term assets ($1.07B) exceed... subscribe to Premium to read more.
Financials
VIR's debt to equity ratio... subscribe to Premium to read more.
Financials

Cash flow

Operating
-$105.8M
Investing
$73.9M
Financing
$3.6M
VIR's cash and short-term investments... subscribe to Premium to read more.
Financials

Vir Biotechnology Stock FAQ

What is Vir Biotechnology's quote symbol?

(NASDAQ: VIR) Vir Biotechnology trades on the NASDAQ under the ticker symbol VIR. Vir Biotechnology stock quotes can also be displayed as NASDAQ: VIR.

What is the 52 week high and low for Vir Biotechnology (NASDAQ: VIR)?

(NASDAQ: VIR) Vir Biotechnology's 52-week high was $83.50, and its 52-week low was $29.48. It is currently -62.44% from its 52-week high and 6.38% from its 52-week low.

How much is Vir Biotechnology stock worth today?

(NASDAQ: VIR) Vir Biotechnology currently has 130,880,159 outstanding shares. With Vir Biotechnology stock trading at $31.36 per share, the total value of Vir Biotechnology stock (market capitalization) is $4.10B.

Vir Biotechnology stock was originally listed at a price of $14.02 in Oct 11, 2019. If you had invested in Vir Biotechnology stock at $14.02, your return over the last 2 years would have been 123.68%, for an annualized return of 49.56% (not including any dividends or dividend reinvestments).

How much is Vir Biotechnology's stock price per share?

(NASDAQ: VIR) Vir Biotechnology stock price per share is $31.36 today (as of Jan 25, 2022).

What is Vir Biotechnology's Market Cap?

(NASDAQ: VIR) Vir Biotechnology's market cap is $4.10B, as of Jan 26, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vir Biotechnology's market cap is calculated by multiplying VIR's current stock price of $31.36 by VIR's total outstanding shares of 130,880,159.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.